Tourette syndrome is a neurological disorder characterized by repetitive, uncontrollable movements and/or unwanted vocal sounds (tics) and typically begins in childhood. Tics range from mild to severe and can therefore significantly affect communication, daily functioning, and quality of life. Aripiprazole, pimozide, and haloperidol are the only therapies with formal approval in either the United States or Europe for Tourette syndrome, but alpha-2 agonists and dopamine-depleting agents are also used off-label. Because pharmacological treatments are usually only partially effective for controlling tics and carry unwanted side effects including somnolence, weight gain, and drug-induced movement disorders, substantial unmet need persists for more effective treatment options.


  • What are the treatment drivers and goals for Tourette syndrome?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • What are the prevailing areas of unmet need and opportunity in Tourette syndrome?
  • What are the commercial opportunities for emerging Tourette syndrome therapies, such as Teva’s deutetrabenazine, Therapix Biosciences’ dronabinol / palmitoylethanolamide, Emalex Biosciences’ ecopipam, and Abide / Lundbeck’s ABX 1431?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new Tourette syndrome drug?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European neurologists fielded in January 2020

Key companies: Janssen, Lundbeck, Otsuka Pharmaceutical, Teva, Emalex Biosciences

Key drugs: Aripiprazole, clonidine, guanfacine, pimozide, risperidone, tetrabenazine, tiapride

Table of contents

  • Detailed, Expanded Analysis (US/FR/DEU/UK)
    • Executive Summary
      • Unmet Need - Tourette Syndrome - Executive Summary - March 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Tourette Syndrome
      • Key Findings: Unmet Need in Tourette Syndrome and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Tourette Syndrome Market and Emerging Therapy Insights
        • Opportunity: A Tourette Syndrome Therapy with An Improved Risk/Benefit Profile
      • Lack of Opportunity in the Tourette Syndrome Market and Emerging Therapy Insights
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Tourette Syndrome Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulation of a Market Scenario
        • Market Scenario
    • Appendix
      • Bibliography

Author(s): Natalie Taylor, PhD

Natalie Taylor, is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a in Biology from Dickinson College in Carlisle, Pennsylvania.